Transforming health in lower-income populations

At Novartis, we have a long-standing history in addressing global health challenges. Over the past 20 years, our approach has evolved from purely donation-based toward models with more sustainable social impact. Today, we apply our expertise and full organizational capability to address major, unresolved global health challenges.

Orange gradient icon of a first aid kit

Patient-first approach

We prioritize the needs of patients, their families and communities, finding innovative ways to overcome barriers to sustainable healthcare delivery.

Orange gradient icon of a microscope

Disease-focused innovation

We focus our scientific expertise to deliver medicines and healthcare solutions, targeting disease areas where we can transform lives.

Orange gradient icon of a bottle

Healthcare for underserved populations

We work to make medicines and healthcare solutions accessible, irrespective of geography, income or local health system limitations.

compass orange gradient icon_0

Health systems strengthening

We work with multiple stakeholders to improve healthcare provision and create new opportunities for medical innovation to benefit lower-income populations.

Orange gradient icon of a handshake

Partnering with commitment

We engage for the long term, working with partners and communities to bring complementary expertise and integrated solutions to address global health challenges.

Orange gradient icon of an ear

Listening to society

We listen to what society expects from us and use the insights to determine where we focus, and how we can deepen our role as a responsible citizen.

Orange gradient icon of a shield

Ensuring impact

Our programs are designed using rigorous goal-setting methodologies to ensure we measure and deliver true societal impact.

Global Health Programs

We aim to adopt an integrated end-to-end approach to disease management for the elimination or control of four diseases where there has been market failure and little investment in research and development. We focus our efforts on four flagship programs in malaria, sickle cell disease, Chagas disease and leprosy, while also taking a coordinated approach to tackling other pressing global health challenges such as avoidable blindness and antimicrobial resistance.

Nurse visits child with malaria in Kenya


We have been committed to the fight against malaria for the past two decades. Today we are working on the development of the next generation of antimalarials.

Treating sickle cell disease

Sickle cell disease (SCD)

Novartis is pursuing a comprehensive approach to tackling SCD. We are developing innovative new medicines to treat it and are working to expand access to diagnosis, treatment and care.

Chagas disease patient in Bahia, Brazil

Chagas disease

Together with partners, we are committed to reimagining the fight against Chagas disease and advocating for an integrated, end-to-end care approach.

Screening child for leprosy in Asia


For more than 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy – and we are committed to going the last mile.

Bacteria in petri dish

Pandemic Preparedness

Climate change and habitat encroachment have led to increased human-wildlife interactions, contributing to rising infectious disease threats. At the same time, the misuse, underuse, and overuse of antibiotics have made antimicrobial resistance one of the top 10 public health threats according to the World Health Organization.